Open Access
The next steps for chemo-optimization in lung cancer treatment
Vis Cancer Med, 6 (2025) 8
Published online: 11 June 2025
Visualized Cancer Medicine
Visualized Cancer Medicine is an interdisciplinary and peer-reviewed journal, which publishes the advances in basic, translational, and clinical studies on cancer biology, cancer prevention, cancer screening and diagnosis, cancer treatments, and cancer patient rehabilitation, with an emphasis on videos presenting the natural process, interventional procedure, and spatial alteration of the studied objects.
Visualized Cancer Medicine is the official journal of the Society of Tumor Microenvironment, China Anti-Cancer Association.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
-
-
Open Access
Revisiting the role of cell death in cancer – promotion rather than inhibition
Vis Cancer Med, 6 (2025) 7Published online: 03 May 2025 -
Open Access
Cancer therapeutics hope: microRNA clinical practice and perspectives
Vis Cancer Med, 6 (2025) 6Published online: 20 April 2025 -
Open AccessReview
Review of radiotherapy combined with systemic therapy for advanced esophageal cancer: from chemotherapy to immunotherapy era
Vis Cancer Med, 6 (2025) 5Published online: 04 April 2025 -
Open Access
Targeting myofibroblastic cancer-associated fibroblasts (myCAFs): a promising strategy for overcoming tumor progression and immunotherapy resistance
Vis Cancer Med, 6 (2025) 4Published online: 17 March 2025 -
Open Access
Enabling clinical use of linear energy transfer in proton therapy for head and neck cancer – A review of implications for treatment planning and adverse events study
Vis Cancer Med, 6 (2025) 3Published online: 20 February 2025 -
Open Access
Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
Vis Cancer Med, 6 (2025) 1Published online: 22 January 2025 -
Open Access
Grisotti flap for central quadrant breast tumours: quick, cosmetic and easy to learn – a case series
Vis Cancer Med, 6 (2025) 2Published online: 22 January 2025
| 236 |
Open Access
Review
Metastasis of nasopharyngeal carcinoma: What we know and do not knowVis Cancer Med, 2 (2021) 4
Published online: 11 August 2021
|
| 175 |
Open Access
Review
Comparison of cyclotron and synchrotron in particle therapyVis Cancer Med, 5 (2024) 7
Published online: 31 July 2024
|
| 135 |
Open Access
Review
Updates on altered signaling pathways in tumor drug resistanceVis Cancer Med, 5 (2024) 6
Published online: 22 July 2024
|
| 120 |
Open Access
Review
CBP/p300 bromodomain: new promising epigenetic targetVis Cancer Med, 3 (2022) 3
Published online: 12 September 2022
|
| 95 |
Open Access
Enabling clinical use of linear energy transfer in proton therapy for head and neck cancer – A review of implications for treatment planning and adverse events studyVis Cancer Med, 6 (2025) 3
Published online: 20 February 2025
|
| 13 |
Open Access
Review
Metastasis of nasopharyngeal carcinoma: What we know and do not knowVis Cancer Med, 2 (2021) 4
Published online: 11 August 2021
|
| 12 |
Open Access
Review
Functions of glutaminyl cyclase and its isoform in diseasesVis Cancer Med, 4 (2023) 1
Published online: 06 January 2023
|
| 11 |
Open Access
An increase in early cancer detection rates at a single cancer center: Experiences from Sun Yat-sen University Cancer CenterVis Cancer Med, 3 (2022) 1
Published online: 01 March 2022
|
| 10 |
Open Access
Spatially-resolved proteomics and transcriptomics: An emerging digital spatial profiling approach for tumor microenvironmentVis Cancer Med, 2 (2021) 1
Published online: 03 March 2021
|
| 5 |
Open Access
Review
MxA: a broadly acting effector of interferon-induced human innate immunityVis Cancer Med, 3 (2022) 2
Published online: 06 April 2022
|
